Download Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2860735/
Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs,
World Market
Description:
The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical
market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics,
Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the
direction it is headed in the next four years.
Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a
determined amount of time causing distress or emotional/physical impairment. Depression, anxiety,
psychosis, ADHD and nicotine and drug dependence are among the conditions psychotherapeutics treat.
Well-known brands such as Prozac™, Zoloft™ and Ritalin ™ have made this a $37 billion market. And
according to Kalorama’s research, revenues from this area will grow more than 50% by 2010.
Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Marketcovers this
market completly including an overview; surveys of the key corporate players, geographic market
breakdowns, and revenue forecasts to 2010 in these key market segments:
Antidepressants
Antipsychotics/Antimanics
Antianxiety Drugs
Stimulants and Non-stimulants for ADHD
Smoking Cessation Drugs, Drug Addiction Treatments, Eating Disorder Treatments and Other
Psychotherapeutics
In every category of psychotherapeutics, new competitors are emerging. Kalorama’s report provides
profiles of thirty-six new psychotherapeutic drugs in the pipeline, their expected approval status, and how
they may shake up the marketplace - as well as a complete discussion of the issues and trends that will
effect psychotherapeutics.
The report also includes current issues and trends affecting the industry including the increasing number of
additional indications pharma companies are seeking for their brands and success stories in this area.
Over 110 tables and figures clearly demonstrate the current and future psychotherapeutic markets.
As part of our complete coverage, the following companies are profiled:
Astellas Pharma, Inc.
AstraZeneca Plc
Biovail Corporation
Bristol-Myers Squibb
Eli Lilly & Company
Forest Laboratories, Inc.
GlaxoSmithKline Plc
H. Lundbeck A/S
Johnson & Johnson
Otsuka Pharmaceutical Co. Ltd.
Pfizer, Inc.
Shire Pharmaceuticals Group Plc
Wyeth
Kalorama’s trusted information-gathering process provides the most accurate study of the market for antidepressants, anti-anxiety drugs, ADHD treatments and other psychotherapeutic drugs available today.
Information and analysis presented in this report is based on extensive interviews with senior management
of top companies and in the psychotherapeutics market. While financial reports, major research literature
and government information is culled, information is corroborated and key market insights originate from
interviews with industry leaders.
Product managers, marketing managers, business development executives, advertising agency or
investment firm executives, as well as information and research center librarians are among the individuals
who will find this survey of the changing psychotherapeutics market essential.
Kalorama’s Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Market
provides coverage of the following brands:
Nardil
Parnate
Prozac
Paxil
Zoloft
Celexa
Lexapro
Effexor and Effexor XR
Cymbalta
Wellbutrin and Wellbutrin XL and Wellbutrin SR
Serzone
Desyrel
Remeron
Symbyax
Tolvon
Xanax
Ativan
Klonopin
Valium
Versed
BuSpar
Lexotan
Paxil/Seroxat and Paxil CR
Zoloft
Ritalin
Focalin and Focalin XR
Daytrana
Strattera
Concerta
Metadate CD
Adderall and Adderall XR
Chantix/Champix
Zyban
Accomplia
Nicotrol
Subutex
Campral
Methodone
ReVia/Naltrex
Antabuse
Narcan
Vivitrol
Depade
YAZ
SSRIs
Compazine, Serentil, Stelazine, Thorazine
Geodon
Zyprexa
Risperdal, Risperdal Consta
Clozaril
Seroquel
Abilify
Lithobid, Eskalith
Symbyax
Lamictal
EMSAM
Contents:
Chapter One: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Competitive Summary
Company Profiles
Chapter Two: Introduction
Conditions
Depressive Disorders
Depression
Seasonal Affective Disorder
Psychotic Disorders
Bipolar Disorder
Schizophrenia
Anxiety Disorders
Attention Deficit Disorders
Eating Disorders
Addiction Disorders
Condition Statistics
Depression
Dysthymic Disorder
Seasonal Affective Disorder (SAD)
Bipolar Disorder
Psychomotor Agitation
Tourette Syndrome
Schizophrenia
Generalized Anxiety Disorder
Social Anxiety Disorder
Obsessive Compulsive Disorder
Panic Disorder
Post Traumatic Stress Disorder
Phobias
Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)
Nicotine, Alcohol, and Drug Addiction
Bulimia/Anorexia
Premenstrual Dysphoric Disorder
History and Growth of the Psychotherapeutic Drug Market
Industry Structure and Product Segments
chapter Three: Antidepressants
Overview
Description of Depression
Epidemiology of Depression
Economic Impact of Depression
Description of Products
Monoamine Oxidase Inhibitors
Nardil
Parnate
Selective Serotonin Reuptake Inhibitors
Prozac/Sarafem
Paxil/Seroxat and Paxil CR
Zoloft
Celexa
Lexapro
Serotonin and Norepinephrine Reuptake Inhibitors
Effexor and Effexor XR
Cymbalta
Aminoketones
Wellbutrin and Wellbutrin XL and Wellbutrin SR
Phenylpiperazines
Serzone
Desyrel
Tetracyclics and Miscellaneous
Remeron
Symbyax
Tolvon
EMSAM
Products in Research and Development
Desvenlafaxine succinate
Gepirone ER
Vilazodone
Seroquel SR
Saredutant (SR 48968)
SR 58611
DOV 216,303
Corlux
Valdoxan
Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
chapter Four: Antipsychotics and Antimanics
Overview
Description of Conditions
Schizophrenia
Bipolar Disorder
Tourette’s Syndrome
Epidemiology
Economic Impact
Description of Products
Phenothiazines
Compazine, Serentil, Stelazine, Thorazine
Geodon
Thienobenzodiazepines
Zyprexa
Benzisoxazole Derivatives
Risperdal, Risperdal Consta
Dibenzodiazepine and Dibenzothiazepine Derivatives
Clozaril
Seroquel
Dopamine Partial Agonist
Abilify
Lithium
Lithobid, Eskalith
Miscellaneous
Symbyax
Lamictal
Research and Development
Paliperidone, Paliperidone ER, Paliperidone Palmitate IM
Asenapine
Bifeprunox
Lamictal
Iloperidone (Zomaril)
LIC 477D
Seroquel SR
Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
chapter Five: Antianxiety Drugs
Overview
Description of Conditions
Economic Impact
Description of Products
Benzodiazipines
Xanax
Ativan
Klonopin
Valium
Versed
Miscellaneous Antianxiety Agents
BuSpar
Lexotan
Prozac/Sarafem
Paxil/Seroxat and Paxil CR
Zoloft
Effexor and Effexor XR
Research and Development
Cipralex
Cymbalta
Lyrica
Desvenlafaxine succinate
DOV 216,303
PDX 00023
Gepirone ER
Saredutant (SR 48968)
SR 58611
Valdoxan
Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER SIX: CNS Stimulants and Nonstimulant Attention Deficit Hyperactive Disorder Treatments
Overview
Description of Conditions
Economic Impact
Description of Products
Amphetamines
Ritalin
Focalin and Focalin XR
Daytrana
Selective Norepinephrine Reuptake Inhibitors
Strattera
Central Nervous System Stimulants
Concerta
Metadate CD
Sympathomimetic Amines
Adderall and Adderall XR
Research and Development
NRP104/LDX
Guanfacine ER (SPD-503)
SPD-465
Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market
Competitive Analysis
chapter Seven: Other Psychotherapeutic Drugs
Overview
Description of Conditions
Eating Disorders - Anorexia and Bulimia
Substance Abuse - Alcohol, Narcotic, Nicotine
Premenstrual Dysphoric Disorder
Economic Impact
Description of Products
Smoking Cessation
Chantix/Champix
Zyban
Accomplia
Nicotrol
Alcohol and Opiate Dependence and Related
Subutex
Campral
Methodone
ReVia/Naltrex
Antabuse
Narcan
Vivitrol
Depade
Bulimia/Anorexia
Prozac
Premenstrual Dysophoric Syndrome
YAZ
SSRIs
Research and Development
Acomplia
Lofexidine
Naltrexone Depot
Lybrel
SSR591813
Cyt002-NicQb
NicVAX
Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan and ROW Market
Market Data by Indication
Competitive Analysis
Chapter Eight: Issues and Trends Affecting the Psychotherapeutic Drug Market
introduction
Patent Expiration Tactics
Smoking Cessation and Genetic Testing
New Drug Targets
ADHD Drugs
Caring Across Communities Program
Prescription Drug Abuse
Drug Advertising and Promotion
Chapter Nine: The Evolving Psychotherapeutic
Drug Market:
Market Forecasts
Overview
Total market Size and Forecast
Competitor Analysis
chapter TeN: Company Profiles
Introduction
Competitive Summary
Astellas Pharma, Inc.
AstraZeneca Plc
Biovail Corporation
Bristol-Myers Squibb
Eli Lilly & Company
Forest Laboratories, Inc.
GlaxoSmithKline Plc
H. Lundbeck A/S
Johnson & Johnson
Otsuka Pharmaceutical Co. Ltd.
Pfizer, Inc.
Shire Pharmaceuticals Group Plc
Wyeth
Appendix
Company Directory
List of Exhibits
Chapter One: Executive Summary
Table 1-1: Market Summary: Total World Psychotherapeutic
Drug Market 2003-2010
Figure 1-1: Trending in the World Market for Psychotherapeutic Drugs 2003-2010
Chapter TWO: INTRODUCTION
Table 2-1: Estimated World and U.S. Prevalence of Psychotic Conditions
or Disorders
Figure 2-1: Estimated World Prevalence of Psychotic Conditions or Disorders
Figure 2-2: Estimated U.S. Prevalence of Psychotic Conditions or Disorders
Chapter THREE: ANTIDEPRESSANTS
Table 3-1: Estimated World and U.S. Prevalence of Depression
Figure 3-1: Estimated World and U.S. Prevalence of Depression
Table 3-2: Recent FDA Antidepressant Approvals, 2003-2006 (Product, Generic Name,
Manufacturer/Marketer, Approval Date, Patent Expiration Date)
Table 3-3: Antidepressants in Research and Development (Product, Developer, Indication, Phase)
Table 3-4: The World Market for Antidepressant Drugs 2003-2010
Figure 3-2: Trending in the World Market for Antidepressant Drugs, 2003-2010
Table 3-5: The World Market for Antidepressant Drugs by Product Classification (SSRIs, S/NRIs, Others)
2003-2010
Figure 3-3: Trending in the World Market for Antidepressant Drugs by
Product Class, 2003-2010
Figure 3-4: Revenue Distribution by Product Class in the World Market for Antidepressant Drugs, 20032010
Table 3-6: The World Market for Antidepressant Drugs by Geographical Segment (U.S., European Union,
Japan, ROW) 2003-2010
Figure 3-5: Trending in the Regional Markets for Antidepressant 2003-2010
Table 3-7: Estimated Antidepressant Sales by Indication (Depression and Major Depressive Disorder vs
Seasonal Affective Disorder), 2005
Table 3-8: The World Market for Antidepressant Drugs Revenues and Market Share of Leading Suppliers
Esitmated 2005 and Projected 2010
Figure 3-6: Leading Suppliers’ Shares of the World Antidepressant
Drug Market 2005
Figure 3-7: Leading Suppliers’ Shares of the World Antidepressant
Drug Market 2010
Table 3-9: Estimated Sales and Market Share of Top Antidepressant Drugs 2005
Figure 3-8: Leading Products’ Shares of the World
Antidepressant Drug Market 2005
Chapter FOUR: ANTIPSYCHOTICS AND ANTIMANICS
Table 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
Figure 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
Table 4-2: Recent FDA Antipsychotic/Antimanic Approvals, 2003-2006 (Product, Generic Name,
Manufacturer/Marketer, Approval Date, Patent Expiration Date)
Table 4-3: Antipsychotics and Antimanics in Research and Development (Product, Developer, Indication,
Phase)
Table 4-4: World Market : Antipsychotic and Antimanic Drugs, 2003-2010
Figure 4-2: World Market Antipsychotic and Antimanic Drugs, 2003-2010
Table 4-5:: World Market: Antipsychotic and Antimanic Drugs by Product
Classification, 2003-2010
Figure 4-3: World Market Antipsychotic and Antimanic Drugs by Product Classification
Revenues, 2003-2010
Figure 4-4 World Market: Antipsychotic and Antimanic Drugs by Product Classification and Percent
Distribution, 2003-2010
Figure 4-5 : World Market Antipsychotic and Antimanic Drugs by Product Classification
and Percent Market Share, 2005
Figure 4-6: World Market and Antimanic Drugs by Product Classification and Percent Market Share, 2010
Table 4-6: World Market Antipsychotic and Antimanic Drug Market
by Geographical Segment, 2003-2010
Figure 4-7: World Market Antipsychotic and Antimanic Drug Market by
Geographical Segment, 2003-2010
Figure 4-8 World Market Antipsychotic and Antimanic Drug Market by
Geographical Segment Percent Distribution, 2003-2010
Figure 4-9 World Market Antipsychotic and Antimanic Drug Market
by Geographical Segment and Percent Market Share, 2005
Figure 4-10: World Market Antipsychotic and Antimanic Drug Market by
Geographical Segment and Percent Market Share, 2010
Table 4-7: Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
Figure 4-11 Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
Table 4-8: World Market : Antipsychotic and Antimanic Drug: Leading Suppliers
Shares by Market Revenues, Estimated 2005 and Projected 2010
Figure 4-12: World Market: Antipsychotic and Antimanic Drugs
Leading Suppliers Market Share, Estimated 2005
Table 4-9: Antipsychotic and Antimanic Drug Market, 2003-2010; Top Antipsychotic and Antimanic Drugs
by Estimated Sales and Percent of Market, 2005
Figure 4-13: Antipsychotic and Antimanic Drug Market, 2003-2010 ; Top Antipsychotic and
Antimanic Drugs by Estimated Sales and Percent of Market, 2005
Chapter FIVE: ANTIANXIETY DRUGS
Table 5-1: Estimated World and U.S. Prevalence of Conditions
Figure 5-1: Estimated World and U.S. Prevalence of Conditions
Table 5-2: Research and Development: Antianxiety Drugs
Table 5-3: World Market Antianxiety Drugs, 2003-2010
Figure 5-2: World Market Antianxiety Drugs, 2003-2010
Table 5-4: World Market: Drugs by Product Classification, 2003-2010
Figure 5-3 World Market Antianxiety Drugs
by Product Classification Revenues, 2003-2010
Figure 5-4 World Market Antianxiety Drugs by Product Classification and Percent Distribution, 2003-2010
Table 5-5: Antianxiety Drugs by Product Classification and
Percent Distribution, 2003-2010
Figure 5-5 Antianxiety Drugs by Product Classification
and Percent Market Share, 2005
Figure 5-6 World Market: Antianxiety Drugs by Product Classification
and Percent Market Share, 2010
Table 5-5: World Market: Antianxiety Drug Market by Geographical Segment,
2003-2010
Figure 5-7: World Market Antianxiety Drug Market by
Geographical Segment, 2003-2010
Figure 5-8: World Market: Drug Market by Geographical Segment Percent Distribution, 2003-2010
Figure 5-9: World Market Antianxiety Drug Market by Geographical Segment and Percent Market Share,
2005
Figure 5-10: Market Drug Market by Geographical Segment and Percent Market Share, 2010
Table 5-6: Estimated Antianxiety Drug Sales by Indication, 2005
Figure 5-11: Antianxiety Drug Sales by Indication, 2005
Table 5-7: World Market: Antianxiety Drugs: Leading Suppliers Shares by Market Revenues, Estimated 2005
and Projected 2010
Figure 5-12: Market Antianxiety Drugs Leading Suppliers Market Share,
Estimated 2005
Figure 5-13: World Market Antianxiety Drugs: Suppliers Market Share,
Projected 2010
Table 5-8: Antianxiety Drug Market, 2003-2010
Top Antianxiety Drugs by Estimated Sales and Percent of Market, 2005
Figure 5-14: Drug Market, 2003-2010 Top Antianxiety Drugs
by Estimated Sales and Percent of Market, 2005
Chapter SIX: CNS STIMULANTS AND NONSTIMULANT ATTENTION DEFICIT HYPERACTIVE DISORDER
TREATMENTS
Table 6-1: Estimated World and U.S. Prevalence of Conditions
Figure 6-1: Estimated World and U.S. Prevalence of Conditions
Table 6-2: Recent Stimulant Approvals, 2003-2006
Table 6-3: Research and Development: Stimulants
Table 6-4 World Market Stimulants and Non-Stimulants
in the ADHD Market, 2003-2010
Figure 6-2: World Market: Stimulants and Non-Stimulants
in the ADHD Market, 2003-2010
Table 6-5: World Market: Stimulants and Non-Stimulants in the ADHD Market
by Geographical Segment, 2003-2010
Figure 6-3: World Market: Stimulants and Non-Stimulants in the ADHD Market
by Geographical Segment, 2003-2010
Figure 6-4: World Market: Stimulants and Non-Stimulants in the ADHD Market
by Geographical Segment Percent Distribution, 2003-2010
Figure 6-5: World Market : Stimulants and Non-Stimulants in the ADHD Market by
Geographical Segment and Percent Market Share, 2005
Figure 6-6: World Market: Stimulants and Non-Stimulants in the ADHD Market by
Geographical Segment and Percent Market Share, 2010
Table 6-6: World Market: Stimulants and Non-Stimulants in ADHD Treatment Leading Suppliers Shares by
Market Revenues,
Figure 6-7: World Market: Stimulants and Non-Stimulants in ADHD Treatment
Figure 6-8: World Market: Stimulants and Non-Stimulants in ADHD Treatment
Table 6-7: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
Figure 6-9: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
CHAPTER SEVEN: OTHER PSYCHOTHERAPEUTIC DRUGS
Table 7-1: Estimated World Prevalence of Conditions
Figure 7-1: Estimated World Prevalence of Conditions
Table 7-2: Recent Other Psychotherapeutic Drug Approvals
Table 7-3: and Development: Other Psychotherapeutic Drugs
Figure 7-2: Research and Development: Other Psychotherapeutic Drugs
Table 7-4: World Market: Other Psychotherapeutic Drugs, 2003-2010
Figure 7-2: World Market: Other Psychotherapeutic Drugs, 2003-2010
Table 7-5: World Market:Other Psychotherapeutic Drugs by
Product Classification, 2003-2010
Figure 7-3: Other Psychotherapeutic Drugs by Product Classification Revenues,
Figure 7-4: Other Psychotherapeutic Drugs by Product
Classification and Percent Distribution,
Figure 7-5: Other Psychotherapeutic Drugs by Product Classification
and Percent Market Share, 2005
Figure 7-6: Other Psychotherapeutic Drugs by Product Classification
and Percent Market Share, 2010
Table 7-6: Other Psychotherapeutic Drug Market by Geographical Segment
Figure 7-7: World Market:Other Psychotherapeutic Drug Market by Geographical Segment, 2003-2010
Figure 7-8
Segment Percent Distribution, 2003-2010
Figure 7-9: Market: Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share,
2005
Figure 7-10: World Market: Other Psychotherapeutic Drug Market by Geographical Segment and Percent
Market Share, 2010
Table 7-5: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005 (in million of dollars at the
manufacturers level)
Figure 7-11: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005
Table 7-7: World Market Other Psychotherapeutic Drugs Leading Suppliers Shares by Market Revenues,
Estimated 2005 and Projected 2010
Figure 7-12: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Estimated 2005
Figure 7-13: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Projected 2010
Table 7-8: Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of
Market, 2005 (in million of dollars at the manufacturers level)
Figure 7-14: Other Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent
of Market, 2005
CHAPTER EIGHT: ISSUES AND TRENDS AFFECTING THE PSYCHOTHERAPEUTIC DRUG MARKET
Table 8-1: Patent Data
CHAPTER NINE: THE EVOLVING PSYCHOTHERAPEUTIC DRUG MARKET
Table 9-1: Psychotherapeutic Drug Market, 2003-2010
Figure 9-1: Psychotherapeutic Drug Market, 2003-2010
Figure 9-2: Psychotherapeutic Drug Market by Percent and
Treatment Segment, 2005
Figure 9-3: Psychotherapeutic Drug Market by Percent
and Treatment Segment, 2010
Table 9-2: Leading Suppliers, Products, and Segments of Participation 2005
Figure 9-4: Leading Suppliers Market Shares 2005
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2860735/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World
Market
Web Address:
http://www.researchandmarkets.com/reports/2860735/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 995
Hard Copy:
USD 3900 + USD 58 Shipping/Handling
Electronic (PDF) Enterprisewide:
USD 7000
* Shipping/Handling is only charged once per order.
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 1 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World